Vivimed To Pay $1.9M To End Losartan Economic Loss Claims
Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood...To view the full article, register now.
Already a subscriber? Click here to view full article